Extracting and calibrating population evidence of variant pathogenicity using biobank data - Bhat, Vineel; Yu, Tian; Brown, Lara; Pejaver, Vikas; Lebo, Matthew; Harrison, Steven; Cassa, Christopher A. (medRxiv, 2024)
Advancing genomic medicine relies on our ability to assess the phenotypic impacts of rare germline variants, which remains challenging even in highly sequenced monogenic disease genes. Here, we evaluate the use of population sequencing data from the UK Biobank to identify variants which alter disease risk, focusing on familial hypercholesterolemia (FH), hereditary breast and ovarian cancer syndrome (HBOC), and Lynch syndrome (CRC). We model evidence of pathogenicity from population data at the variant level, and demonstrate that odds ratios generated from population cohort data can significantly separate ClinVar pathogenic and benign variants in FH genes (p = 4.5x10-19), HBOC genes (p = 2.5x10-39), and CRC genes (p = 7.6x10-16). Next, to make use of this information in variant assessment, we calibrate population-based odds ratios (ACMG/AMP PS4) at the gene level, and find that they reach ‘strong’ or ‘very strong’ evidence of pathogenicity in 8 of 11 genes, as well as in aggregate. Among participants with a rare variant in these 8 genes, 4.3% (N = 2,456) have a Variant of Uncertain Significance (VUS) or variant not yet observed in ClinVar with strong population evidence of pathogenicity that could inform variant interpretation for a related disorder. In three genes with functional assays, we combine this population evidence with computational, contextual, and experimental evidence. Notably, 12.4% of LDLR VUS seen in participants have sufficient evidence to be classified as pathogenic. This method offers a scalable approach to integrate evidence of pathogenicity from population data.HighlightsUses population data to identify rare coding variants which increase risk of clinically actionable phenotypes.Population-based disease odds ratios accurately distinguish ClinVar pathogenic and benign variants.Calibrates odds ratios at the gene level to identify their strength of evidence for variant classification.Combines various evidence types to reclassify a substantial fraction of variants of uncertain significance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe gratefully acknowledge funding from NIH R01HG010372 (V.B., T.Y., L.B., C.A.C.), NIH R01HG013350 (V.P.) and R56HG012681 (T.Y., C.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham IRB gave ethical approval for this work (protocol 2020P002093). Work was performed under UK Biobank application 41250.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPopulation-based variant odds ratios and the underlying case-control data used in their calculation are available at https://doi.org/10.6084/m9.figshare.c.7169472.v1 for all genes studied.